MAI Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.1K Sell
15,879
-742
-4% -$1.25K ﹤0.01% 2659
2025
Q4
$27.8K Sell
16,621
-1,796
-10% -$3.11K ﹤0.01% 2343
2025
Q3
$31.1K Sell
18,417
-637
-3% -$754 ﹤0.01% 2186
2025
Q2
$17.3K Sell
19,054
-45,337
-70% -$26.9K ﹤0.01% 2418
2025
Q1
$29.1K Sell
64,391
-593,288
-90% -$348K ﹤0.01% 2021
2024
Q4
$330K Sell
657,679
-1,017,000
-61% -$747K ﹤0.01% 965
2024
Q3
$1.52M Buy
1,674,679
+35,907
+2% +$33.3K 0.01% 456
2024
Q2
$1.63M Buy
1,638,772
+147,910
+10% +$163K 0.02% 458
2024
Q1
$2.21M Buy
1,490,862
+687,017
+85% +$779K 0.02% 385
2023
Q4
$876K Sell
803,845
-150,843
-16% -$165K 0.01% 501
2023
Q3
$1.13M Buy
954,688
+3,110
+0.3% +$4.23K 0.02% 408
2023
Q2
$1.34M Buy
951,578
+526,463
+124% +$728K 0.02% 374
2023
Q1
$638K Sell
425,115
-31,702
-7% -$44.3K 0.01% 558
2022
Q4
$534K Sell
456,817
-65,053
-12% -$82K 0.01% 597
2022
Q3
$590K Buy
521,870
+274,135
+111% +$403K 0.01% 506
2022
Q2
$391K Buy
+247,735
New +$327K 0.01% 619

Other funds holding LCTX